X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2242) 2242
Publication (229) 229
Book Review (39) 39
Conference Proceeding (3) 3
Dissertation (2) 2
Magazine Article (2) 2
Book Chapter (1) 1
Data Set (1) 1
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1645) 1645
oncology (1301) 1301
index medicus (1239) 1239
female (982) 982
2nd-line treatment (950) 950
middle aged (837) 837
chemotherapy (836) 836
male (775) 775
aged (755) 755
adult (666) 666
antineoplastic combined chemotherapy protocols - therapeutic use (558) 558
cancer (555) 555
treatment outcome (541) 541
2nd-line chemotherapy (428) 428
2nd-line therapy (367) 367
pharmacology & pharmacy (350) 350
antineoplastic agents - therapeutic use (340) 340
cisplatin (338) 338
care and treatment (330) 330
lung neoplasms - drug therapy (328) 328
open-label (306) 306
phase-ii trial (299) 299
docetaxel (298) 298
double-blind (290) 290
paclitaxel (285) 285
disease-free survival (278) 278
phase-iii trial (267) 267
gemcitabine (260) 260
aged, 80 and over (259) 259
therapy (259) 259
antineoplastic combined chemotherapy protocols - adverse effects (251) 251
1st-line treatment (244) 244
trial (244) 244
carcinoma, non-small-cell lung - drug therapy (240) 240
research (223) 223
carcinoma (219) 219
clinical trials (219) 219
drug therapy (217) 217
survival (207) 207
metastasis (204) 204
drug administration schedule (202) 202
phase-ii (200) 200
deoxycytidine - analogs & derivatives (197) 197
prognosis (195) 195
retrospective studies (194) 194
survival rate (192) 192
analysis (179) 179
neoplasm staging (179) 179
gastroenterology & hepatology (178) 178
medicine & public health (178) 178
survival analysis (175) 175
efficacy (164) 164
supportive care (158) 158
neoplasm metastasis (157) 157
combination (156) 156
hematology, oncology and palliative medicine (156) 156
respiratory system (156) 156
2nd-line (153) 153
carboplatin (152) 152
deoxycytidine - administration & dosage (148) 148
lung cancer (148) 148
lung neoplasms - pathology (147) 147
salvage therapy (145) 145
multicenter (142) 142
neoplasm recurrence, local - drug therapy (140) 140
ovarian neoplasms - drug therapy (140) 140
irinotecan (138) 138
randomized-trial (135) 135
1st-line therapy (133) 133
antineoplastic combined chemotherapy protocols - administration & dosage (133) 133
drug therapy, combination (133) 133
oxaliplatin (132) 132
erlotinib (131) 131
bevacizumab (130) 130
drug resistance, neoplasm (130) 130
health aspects (130) 130
non-small cell lung cancer (130) 130
antineoplastic agents (129) 129
disease progression (129) 129
paclitaxel - administration & dosage (129) 129
cell lung-cancer (128) 128
2nd-line drugs (127) 127
cancer therapies (126) 126
lung cancer, non-small cell (126) 126
patients (125) 125
randomized phase-iii (122) 122
mutation (121) 121
antimitotic agents (119) 119
prospective studies (119) 119
topotecan (119) 119
antineoplastic agents - adverse effects (116) 116
randomized controlled trials as topic (116) 116
taxoids - administration & dosage (116) 116
adenocarcinoma (114) 114
adenocarcinoma - drug therapy (114) 114
cancer research (114) 114
infectious diseases (114) 114
cisplatin - administration & dosage (108) 108
antineoplastic agents - administration & dosage (106) 106
dose-response relationship, drug (106) 106
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2178) 2178
French (32) 32
German (21) 21
Spanish (8) 8
Polish (5) 5
Chinese (1) 1
Russian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 2018, Volume 36, Issue 9, pp. 884 - 890
Purpose Studies suggest that a subset of patients with triple-negative breast cancer (TNBC) have tumors that express the androgen receptor (AR) and may benefit... 
TRIAL | MOLECULAR PORTRAITS | ONCOLOGY | BEVACIZUMAB | SUBTYPES | 2ND-LINE TREATMENT | DOUBLE-BLIND | ABIRATERONE ACETATE | PHASE-II | METASTATIC PROSTATE-CANCER | CHEMOTHERAPY | ORIGINAL REPORTS
Journal Article
The Oncologist, ISSN 1083-7159, 08/2019, Volume 24, Issue 8, pp. 1033 - e617
Lessons Learned In terms of efficacy and safety, good results were obtained with S‐1 and paclitaxel (PTX) combination therapy. The findings suggest that S‐1... 
TRIAL | 2ND-LINE TREATMENT | ONCOLOGY | DOCETAXEL | CHEMOTHERAPY | I/II | Clinical Trial Results
Journal Article
Blood, ISSN 0006-4971, 07/2018, Volume 132, Issue 1, pp. 40 - 48
Autologous stem cell transplantation (ASCT) is standard of care for patients with Hodgkin lymphoma (HL) who have relapsed/refractory disease after frontline... 
TRIAL | 2ND-LINE | THERAPY | VINORELBINE | MULTICENTER PHASE-II | DISEASE | STEM-CELL TRANSPLANTATION | HEMATOLOGY | CHEMOTHERAPY | GEMCITABINE | Index Medicus | Abridged Index Medicus | Clinical Trials and Observations
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 11, pp. 1224 - 1235
Summary Background VEGFR-2 has a role in gastric cancer pathogenesis and progression. We assessed whether ramucirumab, a monoclonal antibody VEGFR-2... 
Hematology, Oncology and Palliative Medicine | SUPPORTIVE CARE | ONCOLOGY | BEVACIZUMAB | CLINICAL-TRIALS | GROWTH | 2ND-LINE CHEMOTHERAPY | OPEN-LABEL | 1ST-LINE THERAPY | COMBINATION | CANCER | III TRIAL | Confidence Intervals | Adenocarcinoma - pathology | Prognosis | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Stomach Neoplasms - pathology | Esophageal Neoplasms - pathology | Dose-Response Relationship, Drug | Esophageal Neoplasms - mortality | Adult | Female | Remission Induction - methods | Paclitaxel - administration & dosage | Double-Blind Method | Drug Administration Schedule | Kaplan-Meier Estimate | Proportional Hazards Models | Esophagogastric Junction - pathology | Paclitaxel - adverse effects | Treatment Outcome | Stomach Neoplasms - drug therapy | Adenocarcinoma - drug therapy | Disease-Free Survival | Maximum Tolerated Dose | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged | Esophageal Neoplasms - drug therapy | Stomach Neoplasms - mortality | Adenocarcinoma - mortality | Antimitotic agents | Care and treatment | Hospitals | Clinical trials | Monoclonal antibodies | Product development | Antineoplastic agents | Vascular endothelial growth factor | Esophageal cancer
Journal Article
PLOS ONE, ISSN 1932-6203, 06/2018, Volume 13, Issue 6
Background The viral load (VL) in patients receiving antiretroviral therapy (ART) is the best predictor of treatment outcome. The anticipated benefits of VL... 
RATES | VIROLOGICAL FAILURE | MULTIDISCIPLINARY SCIENCES | GUIDELINES | ADULTS | 2ND-LINE ANTIRETROVIRAL THERAPY | DRUG-RESISTANCE | OUTCOMES
Journal Article